Low dose aspirin could help protect against death from cancer

Reprinted with permission of Life Extension

An article published online on December 7, 2010 in The Lancet reveals a protective effect of low dose aspirin against the risk of dying from a number of cancers. “These findings provide the first proof in man that aspirin reduces deaths due to several common cancers,” the authors announce.

Peter Rothwell of Oxford University and his colleagues pooled data from 8 randomized trials comparing the use of aspirin to no aspirin or another blood thinning agent to prevent vascular disease. The trials’ treatment periods averaged at least 4 years, and 20 year post-trial follow-up data was available for participants in three trials.

Six hundred seventy-four deaths from cancer occurred during the trials among a total of 25,570 subjects. Those who received aspirin had a 21 percent reduced risk of dying from cancer over the treatment periods compared to those who did not receive the drug. Further analysis found a significant benefit after 5 years of follow-up, with aspirin use associated with a 34 percent lower risk of dying from all cancers and a 54 percent lower risk of dying from gastrointestinal cancer. For the 12,659 participants in the trials that followed patients for 20 years, the risk of dying from all solid cancers remained lower by 20 percent in aspirin users, and by 35 percent for GI cancers, with treatment periods of at least seven and one half years associated with further benefit. Doses of aspirin higher than 75 milligrams were not associated with increased protection. The effects were not dependent upon gender or smoking status, and were greatest for adenocarcinoma.

“Our results have implications for understanding of carcinogenesis, particularly for adenocarcinoma, and they demonstrate the potential for drug intervention in the prevention of cancer,” the authors conclude. “Although the effect of aspirin may be mediated in part by inhibition of COX-2, more research is required, other pro-apoptotic effects early in the development of tumours perhaps also being important.”

“These are very exciting and potentially important findings,” stated Professor Tom Meade of the London School of Hygiene & Tropical Medicine, who conducted one of the trials included in the analysis. “They are likely to alter clinical and public health advice about low dose aspirin because the balance between benefit and bleeding has probably been altered towards using it.”

“These results do not mean that all adults should immediately start taking aspirin, but they do demonstrate major new benefits that have not previously been factored into guideline recommendations,” Dr Rothwell emphasized. “Perhaps the most important finding for the longer-term is the proof of principle that cancers can be prevented by simple compounds like aspirin and that ‘chemoprevention’ is therefore a realistic goal for future research with other compounds.”


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: